Phage Biotechnology Corp. Engages The Bruckner Group to Find a Joint Commercialization Partner for Phage's Portfolio of Recombinant Protein Biopharmaceuticals, Technologies, and Development Platforms  
11/15/2007 9:10:00 AM

LAS VEGAS--(BUSINESS WIRE)--Phage Biotechnology Corp. (“Phage”) has engaged The Bruckner Group to find a partner to jointly commercialize Phage’s portfolio of recombinant biological therapies, the products of Phage’s development platforms and technologies.